Showing results (281-290 of 1,831) with videos related to
Sort By:
Pageof 184
ESMO Open|September 6, 2021
Refining patient selection for breast cancer immunotherapy: beyond PD-L1M Kossai, N Radosevic-Robin, F Penault-LlorcaESMO Open|September 6, 2021
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinomaM Kirchner, K Kluck, R Brandt, et al.ESMO Open|September 20, 2021
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort studyA Lasagna, F Agustoni, E Percivalle, et al.ESMO Open|August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumorsE Borazanci, A M Schram, E Garralda, et al.ESMO Open|May 23, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast CancerEvandro de Azambuja, Dario Trapani, Sibylle Loibl, et al.ESMO Open|April 30, 2021
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancerA Guyot D'Asnières De Salins, G Tachon, R Cohen, et al.ESMO Open|May 3, 2021
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trialsA Galvano, V Gristina, U Malapelle, et al.ESMO Open|May 3, 2021
The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancerA Trullas, J Delgado, A Genazzani, et al.ESMO Open|September 12, 2021
Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patientsA A Kulkarni, N Rubin, A Tholkes, et al.Pageof 184